sabato, 13 luglio 2024
24 Giugno 2019

Statement on the FDA’s benefit-risk framework for evaluating opioid analgesics

June 20, 2019 – Addressing the crisis of opioid addiction is an issue of great concern for our nation and remains a top public health priority for the FDA. The agency continues to take new steps to confront this crisis, while also paying careful attention to the needs of patients in accessing appropriate pain management. Opioids present unique challenges: they have benefits when used as prescribed yet have very serious risks and can cause enormous harm when misused and abused … (leggi tutto)